Recent Articles from GlobeNewswire

BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 228,750 shares of Class A common stock and restricted stock units (RSUs) underlying 116,000 shares of Class A common stock to eighteen (18) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

RUSTON, La., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Origin Bancorp, Inc. (NYSE: OBK) (“Origin”), the financial holding company for Origin Bank, plans to issue fourth quarter and full year 2025 results after the market closes on Wednesday, January 28, 2026, and hold a conference call to discuss such results on Thursday, January 29, 2026, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time). The conference call will be hosted by Drake Mills, Chairman, President and CEO of Origin, William J. Wallace, IV, Chief Financial Officer of Origin, and Lance Hall, President and CEO of Origin Bank.

LAS VEGAS, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Zhejiang Bosuer Motion Apparatus Co., Ltd. (Bosuer), a manufacturer specializing in electric off-road vehicles and an established electric dirt bike supplier, is presenting its latest electric dirt bike innovations at CES 2026, introducing an expanded and refined lineup aimed at accelerating the electrification of the off-road powersports market. At this year’s show, Bosuer is highlighting four core electric off-road motorcycle models — E60, E72, S6 (ES60), and the newly launched S5 — demonstrating the company’s growing technological depth and product breadth in high-performance electric mobility.

East Hanover, N.J., January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida. The built-for-purpose, state-of-the-art facility represents another milestone in the company's $23 billion US investment announced in April 2025, further expanding manufacturing capabilities to meet growing demand for these cutting-edge cancer treatments. Novartis is scaling US manufacturing to bring innovative medicines closer to patients, so treatments are researched, made, and delivered with greater speed, reliability, and access in the communities where people live. The new 35,000-square-foot facility in Winter Park, Florida, will come online by 2029 and will strengthen Novartis’ specialized supply chain and manufacturing capabilities across its network of RLT production facilities. The new facility will optimize the delivery of RLT medicines to patients in the southeast US and help maintain the company’s steady rate of >99% of doses administered on the planned day as the potential for this promising treatment modality continues to expand.“Building this new facility in Florida marks an important step in fulfilling the promise of RLT for patients,” said Vas Narasimhan, CEO of Novartis. “Radioligand therapy has fundamentally changed how we approach certain cancers, and our growing US manufacturing network ensures we can continue to deliver these critical medicines with speed and reliability to patients who need them.”RLT is a type of precision treatment that pairs a tumor-targeting molecule (ligand) with a therapeutic radioisotope, allowing radiation to be delivered directly to the tumor while minimizing harm to surrounding healthy tissue. Each RLT dose is individually prepared, and its delivery is highly time sensitive. Proximity to treatment facilities and transportation hubs is critical to ensure patients receive their therapy promptly and at the right location. RLT has the potential to transform oncology treatment and bring new options to people living with cancer.As the sole company with two FDA-approved RLT treatments and an extensive RLT pipeline across several tumors and targets, Novartis has global expertise in this cutting-edge technology platform that is transforming cancer care. That knowledge has fueled advancements in manufacturing techniques to build capacity and consistently deliver with confidence for patients and healthcare providers.  RLT manufacturing requires specialized talent, a key factor in determining the location for each new facility. Florida has steadily invested in higher education for life sciences and technology, helping to build the next generation of leaders critical to driving forward advanced manufacturing for platforms like RLT. With a growing skilled workforce and a regulatory and policy environment that values pharmaceutical innovation, Florida is well positioned to become a leader in pharmaceutical manufacturing. “Thanks to deliberate, focused, intensified investments and world class health innovation partnerships, we have led Florida to become a national and world-recognized leader for breakthroughs in cancer treatment, neurological innovations, and more,” said Florida Secretary of Commerce J. Alex Kelly. “Novartis’ investment in manufacturing cancer medicines here in Florida—where we’re already #2 nationally in both manufacturing for medicine and medical device technology—is an incredible opportunity to welcome world class innovators to our incredibly collaborative and impactful life sciences community.”Over the next 5 years, Novartis will solidify its robust US RLT manufacturing network. The new Florida site is the fourth of five existing or planned facilities. The company is currently investing in expansions of its RLT facilities in Indiana and New Jersey. In November, Novartis announced completion of a new RLT facility in California, and it plans to build a fifth location in the US. Novartis and radioligand therapy (RLT)Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells anywhere in the body.  Novartis is actively investigating the application of RLTs across cancer types and settings, with one of the deepest and most advanced pipelines in the industry, with trials in prostate cancer, breast, colon, lung, brain, pancreatic and other cancers. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites around the world. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release; or regarding potential future revenues from such products; or regarding discussions of strategy, plans, expectations or intentions, including discussions regarding our continued investment into new US manufacturing and R&D capabilities. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. Neither can there be any guarantee that the expected benefits from the plans and investments described in this press release will be achieved in the expected timeframe, or at all. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.Reimagine medicine with us: Visit us at https://www.novartis.us and connect with us on LinkedIn US, X/Twitter US and Instagram.

Munich, Germany, Jan. 09, 2026 (GLOBE NEWSWIRE) -- On the 31st December 2025, DYWIDAG Systems International (DYWIDAG) completed the sale of 100% of its shares in TAM Groupe (the “Company”), a French market leader in manufacturing and distribution of chemical products, fixing and lifting systems, and accessories for the construction market, to Private Assets SE & Co. KGaA (Private Assets).

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Klarna (KLAR) To Contact Him Directly To Discuss Their Options

Transaction in Own Shares   

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Stride (LRN) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Freeport (FCX) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Firefly (FLY) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Primo Brands (PRMB) To Contact Him Directly To Discuss Their Options

JEFFERSON CITY, Mo., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Central Bancompany, Inc. (Nasdaq: CBC) (“Central Bancompany” or “the Company”), the bank holding company for The Central Trust Bank, will release its fourth quarter 2025 financial results before market hours on Tuesday, January 27, 2026. The Company will host a conference call and webcast at 9:00 a.m. CT on Tuesday, January 27, 2026. The call may include discussion of Company developments, forward-looking statements and other material information about business and financial matters.

PHILADELPHIA, Jan. 09, 2026 (GLOBE NEWSWIRE) --

 Monthly declaration of the total number of shares and voting rights composing the company's capital (at December 31st, 2025)

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this Offering were offered by Bright Minds.

SANTIAGO, Chile, Jan. 09, 2026 (GLOBE NEWSWIRE) -- You are cordially invited to participate in Banco Santander Chile's (NYSE: BSAC) conference call-webcast on Thursday February 5, 2026, at 9.00 AM NY time (11.00am Chile time) where we will discuss 4Q 2025 financial results. The Bank's Officers participating in the conference call are: Patricia Pérez, CFO, Cristian Vicuña, Chief Strategy Officer & Head of IR and Lorena Palomeque, Economist. A question and answer session will follow the presentation.

MONTREAL, Jan. 09, 2026 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced today that it set a new monthly record for grain movement in December, marking its fourth consecutive record month. CN moved over 2.82 million metric tonnes of grain from Western Canada last month, surpassing its previous December record set in 2020 by over 80,000 metric tonnes.

DURHAM, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced an updated presentation time of 11:15 am PST on Tuesday, January 13, 2026, at the J.P. Morgan Annual Healthcare Conference (San Francisco).

Hauppauge, NY, Jan. 09, 2026 (GLOBE NEWSWIRE) --  Cemtrex, Inc. (NASDAQ: CETX) (the “Company”), an advanced security technology and industrial services company, today announced that it has entered into a definitive agreement for the purchase of approximately 1,469,507 shares and / or pre funded warrants with a single institutional investor, at a purchase price of $2.722 per share, with gross proceeds to the Company expected to be $4 million to the Company.

BROOKFIELD, Wis., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Infinity Home Services (IHS), a leading home services platform, today announced a leadership transition designed to support the company’s continued growth and long-term strategy.

LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against F5, Inc. (“F5” or “the Company”) (NASDAQ: FFIV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Westwood One, Official Network Audio Partner of the NFL, Delivers All the Action with Live Play-by-Play Coverage of All Six NFL Games on Saturday, January 10, Sunday, January 11, and Monday, January 12

LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SLM Corporation a/k/a Sallie Mae (“SLM” or “the Company”) (NASDAQ: SLM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Integer Holdings Corporation (“Integer” or “the Company”) (NYSE: ITGR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Latest XRP Market Trend: Entering a “Consolidation and Accumulation Phase”

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Blue Owl To Contact Him Directly To Discuss Their Options

LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gauzy Ltd. (“Gauzy” or “the Company”) (NASDAQ: GAUZ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In F5 To Contact Him Directly To Discuss Their Options

LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bitdeer Technologies Group (“Bitdeer” or “the Company”) (NASDAQ: BTDR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

PHILADELPHIA, Jan. 09, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Klarna Group plc (NYSE: KLAR) (“Klarna” or the “Company”) on behalf of investors who purchased or otherwise acquired Klarna securities during the period of September 7, 2025 through December 22, 2025 (the “Class Period”), including shares issued pursuant and/or traceable to Klarna’s September 2025 initial public offering (“IPO”).

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In SLM To Contact Him Directly To Discuss Their Options

PRESS RELEASE

LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Blue Owl Capital Inc. (“Blue Owl” or “the Company”) (NYSE: OWL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Primo Brands To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fermi To Contact Him Directly To Discuss Their Options

LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DeFi Technologies Inc. (“DeFi” or “the Company”) (NASDAQ: DEFT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options

LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sprouts Farmers Market, Inc. (“Sprouts” or “the Company”) (NASDAQ: SFM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bitdeer To Contact Him Directly To Discuss Their Options

KEY LARGO, Fla., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Remedy's Nutrition®, a pioneering natural health company established in 1972, today announced the launch of its cutting-edge diagnostic service: Hair Tissue Mineral Analysis (HTMA). This comprehensive health package combines laboratory precision with expert guidance, offering six personalized consultations to decode the body's mineral blueprint and optimize metabolic performance.

LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Alexandria Real Estate Equities, Inc. (“Alexandria” or “the Company”) (NYSE: ARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue.

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cabot Corporation (NYSE: CBT) today announced that it will release operating results for the first quarter of fiscal 2026 on Tuesday, February 3, 2026, after the market close. The Company will host a conference call and live webcast to review the first quarter results beginning at 8:00 am (ET) on Wednesday, February 4, 2026.

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that it has entered into a non-binding memorandum (the “Investment Memorandum”) with Future Biotechnology Group Co., Ltd (hereinafter referred to as “Future Biotechnology Group”).

CHAPEL HILL, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IPACE-HIV study (Improving Physical Ability and Cellular Senescence Elimination in HIV), also known as A5426. IPACE-HIV is a phase 2, double-blind, randomized study evaluating the safety, tolerability, and efficacy of dasatinib and quercetin in improving physical function outcomes in people living with HIV who are frail or exhibit symptoms that they may become frail.

Proposed Transaction Expected to Expand Ready-to-Drink Product Portfolio, Enhance White Tea Value Chain, and Broaden Health-Oriented Consumption Scenarios

What To Know: 

Appointments strengthen newcleo's executive team as company advances its nuclear energy and fuel recycling business and prepares for next phase of growth

First Commercial Multi-Site Deployment With a National Construction Leader; Expands a Long-Standing Customer Relationship Across Multiple U.S. States

WASHINGTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, to the Bio-Hermes studies. This collaboration will enhance the unique, observational platform studies that compare blood-based and digital biomarkers across a broad range of clinical cognitive conditions — along with MRI and PET images in Bio-Hermes-002 —as well as numerous races and ethnicities to generate data that may help predict, detect and diagnose Alzheimer’s disease and related dementias.

MIAMI, FL, Jan. 09, 2026 (GLOBE NEWSWIRE) -- RenX Enterprises Corp. (NASDAQ: RENX) (the “Company”) today provided an update on a year that management views as transformational, reflecting a fundamental evolution of the Company’s operating profile, financial performance, and strategic direction.

MONTREAL, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cerro de Pasco Resources Inc. (TSXV CDPR) (OTCQB GPPRF) (FRA N8HP) (the Company or CDPR) is pleased to provide an operational review and corporate update highlighting key workstreams completed and consolidated at the Quiulacocha Tailings Project, as the Company transitions toward the next stage of project execution.

-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies-

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in the company’s quarterly dividend over the previous quarter’s dividend.

- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule

SAN JOSE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nutanix, Inc. (NASDAQ: NTNX), a leader in hybrid multicloud computing, today announced that its management will present at the following upcoming financial community event:

2025 Closes with Accelerating Inflation and Seven Consecutive Month-over-Month Price Increases on Everyday Consumer Goods

Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026

EL MONTE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced that Larry Wu, its Founder and Chief Executive Officer, will present at the 28th Annual Needham Growth Conference on Friday, January 16, 2026, at 2:15 p.m. ET/11:15 a.m. PT.

BEIJING, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Global Mofy AI Limited (the “Company” or “Global Mofy”) (Nasdaq: GMM), a generative AI-driven technology solutions provider engaged in virtual content production and the development of 3D digital assets for use in the broader digital content industry, today announced its financial results for the fiscal year ended September 30, 2025.

-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 --

CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced the appointment of Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer. Dr. Eck brings more than three decades of oncology drug discovery and development leadership across academia, biotechnology and large pharmaceutical companies.

Licensing of scientific discoveries from University of Cambridge and University of Edinburgh is aimed to speed translation and access to life-saving diagnostics for women worldwide.

-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 --

Acquisition Strengthens Data Connectivity Across the Wealth and Private Markets Ecosystem

Members gain access to savings on AMI brands Gentek® Building Products and ASCEND® Composite Cladding

ATLANTA, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Crayhill Capital Management (“Crayhill”) and Monarch Private Capital (“Monarch”) are pleased to announce a strategic joint venture to facilitate hybrid preferred tax equity investments for renewable energy projects, including utility-scale solar, battery storage, and distributed generation projects. Crayhill has committed $300 million of capital into the joint venture, Monarch JVT Funding. Through Monarch’s best-in-class platform, the JV will invest in tax partnerships that will facilitate fair market value tax basis for renewable energy developers.

BERKELEY, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced that it is revising its roadmap and adjusting the date for general availability of its 108-qubit quantum computing system, Cepheus™-1-108Q. Cepheus-1-108Q is now expected to reach general availability around the end of the first quarter of 2026.

RALEIGH, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Attindas Hygiene Partners’ growth strategy realized an important step forward today with its acquisition of Societá Italiana Lavorazione Cellulosa (SILC S.p.A.). Attindas executed a share purchase agreement with SILC, acquiring all shares of the 53-year-old, family-owned company.

LONDON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- NordPass, a leading password manager, simplifies secure logins by including Authenticator on multiple devices in the application for personal use. The time-based one-time password (TOTP) support enables users to add an extra layer of security to their accounts with two-factor authentication, without the need to download or install additional applications. Authentication codes are synchronized within the account, letting users access them on both the mobile app or browser extension.

TORONTO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, today announced the preliminary results of its substantial issuer bid (the “SIB”), pursuant to which Altus Group offered to purchase for cancellation a number of its common shares (“Shares”) for an aggregate purchase price not to exceed C$350 million at a purchase price of not less than C$50.00 and not more than C$57.00 per Share. The SIB expired at 5:00 p.m. (Toronto time) on Thursday, January 8, 2026 (the “Expiration Time”).

Rakesh Panda appointed Chief Information Officer

$3.1 Billion Unsecured Funding Offering Strengthens Capital Structure and Marks Transformational Credit Profile Enhancement